Alpha Tau Medical

Alpha Tau Medical (https://www.alphatau.com/) focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy) for the treatment of solid cancer tumors. Initially developed at Tel Aviv University, Alpha DaRT was shown to be effective and safe for treating different types of cancer in multiple animal studies. The company is running its first clinical trial in several sites in the EU and is currently commencing clinical trials at over 55 leading cancer centers worldwide. Alpha DaRT Breakthrough Cancer Treatment Alpha DaRT enables high-precision alpha radiation for all types of solid tumors. The treatment is delivered by inserting with Radium-224 impregnated seeds into the tumor. When the Radium decays, its short-lived daughters are released from the seed, disperse into the tumor and emit high-energy alpha particles which destroy the tumor. Since the alpha-emitting atoms hardly diffuse in healthy tissue, the Alpha DaRT mainly affects the tumor, sparing the healthy tissue around it. Alpha DaRT has several important advantages: • Highly potent and conformal • Proven efficacy for all solid tumors tested • Enhances systemic anti-tumor immune response • Effective regardless of tumor oxygen level • Short half-life – quick clinical outcome • No known negative systemic effects • Single-session treatment • Enables combination with other therapies or reapplication • Disposable applicators - does not require capital equipment or special shielding